Results 81 to 90 of about 72,871 (224)

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières [PDF]

, 2008
OBJECTIVES: To describe the use of second-line protease-inhibitor regimens in Médecins Sans Frontières HIV programmes, and determine switch rates, clinical outcomes, and factors associated with survival.
Alexandra Calmy, Boyd, Braitstein, Calmy, Calmy, Chaiwarith, Colebunders, Daniel O'Brien, Ferradini, Gallant, Galárraga, Ivers, Laurent, Ledergerber, Mar Pujades-Rodríguez, Mocroft, Nicastri, Orrell, Pierre Humblet, Renaud-Théry, Srasuebkul, Sungkanuparph, Vasan, Vekemans, Walmsley   +24 more
core   +2 more sources

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, EarlyView.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

Towards a Patent Pool for HIV Medicines: The Background [PDF]

, 2010
Recent WHO guidelines for antiretroviral therapy recommend switching to less toxic, but more expensive medicines for first-line and second-line ART, raising questions about the financial sustainability of many AIDS treatment programmes. At the same time,
Childs, Michelle
core   +2 more sources

Altered Pharmacokinetics and Delayed Sputum Conversion in Tuberculosis Patients Co‐Infected With HIV

Tropical Medicine &International Health, EarlyView.
ABSTRACT Background HIV co‐infection affects host responses and pharmacokinetics (PK) of tuberculosis (TB) treatment. This study assessed the PK of first‐line anti‐TB drugs and clinical outcomes in patients with and without HIV co‐infection. Methods In this prospective observational study, 61 adults with sputum‐positive pulmonary TB, either confirmed ...
Aung Pyae Phyo, Richard M. Hoglund, Makoto Saito, Sein Sein Thi, Lei Lei Swe, Palang Chotsiri, Htet Ko Ko Aung, Win Pa Pa Tun, Banyar Maung Maung, Chanapat Pateekham, Wanitda Watthanaworawit, Gornpan Gornsawun, Nicholas J. White, Francois Nosten, Joel Tarning   +14 more
wiley   +1 more source

Pharmacokinetic analysis of placental transfer of ritonavir as a component of paxlovid using microdialysis in pregnant rats

Heliyon
Background: Ritonavir is one of the most potent CYP3A4 inhibitor currently on the market, and is often used together with other antiviral drugs to increase their bioavailability and efficacy.
Chung-Kai Sun, Wan-Hsin Lee, Muh-Hwa Yang, Tung-Hu Tsai   +3 more
doaj   +1 more source

Rapid enzymatic test for phenotypic HIV protease drug resistance [PDF]

, 2003
A phenotypic resistance test based on recombinant expression of the active HIV protease in E. coli from patient blood samples was developed. The protease is purified in a rapid onestep procedure as active enzyme and tested for inhibition by five selected
Assfalg-Machleidt, Irmgard, Helm, K. von der, Hoffmann, D., Koszinowski, U., Machleidt, Werner, Nitschko, H.   +5 more
core   +1 more source

Maternal nutrition as a key determinant of placental and developing blood–brain barrier xenobiotic protective functions

The Journal of Physiology, EarlyView.
Abstract figure legend Suboptimal maternal nutrition alters placental and developing blood–brain barrier (BBB) protective function and is associated with increased fetal brain vulnerability. In the placenta, nutritional adversity may reduce the exchange surface area and promote meta‐inflammation, compromising barrier efficiency in a model‐ and context ...
Kristin L. Connor, Nycolle I. S. Souza, Bruno G. Anjos, Stephen G. Matthews, Enrrico Bloise   +4 more
wiley   +1 more source

Ritonavir [PDF]

Reactions Weekly, 2020
  +4 more sources

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Journal of Virus Eradication, 2018
Background: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC ...
Andrew Hill, Sophie L. Hughes, Dzintars Gotham, Anton L. Pozniak   +3 more
doaj   +1 more source

Characteristics, Immunological Response & Treatment Outcomes of HIV-2 Compared with HIV-1 & Dual Infections (HIV 1/2) in Mumbai [PDF]

, 2010
Information available on HIV-2 and dual infection (HIV-1/2) is limited. This study was carried out among HIV positive individuals in an urban referral clinic in Khar, Mumbai, India, to report on relative proportions of HIV-1, HIV-2 and HIV-1/2 and ...
Alaka, Deshpande, Bhanumati, Varghese, Chiara, Montaldo, Harries, A D, Homa, Mansoor, Ladomirska, Joanna, Manzi, M, Rony, Zachariah, Wilson, N   +8 more
core   +1 more source